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                                           INTRODUCTION 
 
Liver diseases affect millions of people worldwide each day. 
However, in the developing countries where cost of health care has 
always been an issue, long lasting diseases such as liver cirrhosis and 
its complications are a major health problem and pose a big challenge 
to the health economy. Because of poverty, poor hygienic conditions, 
inadequate education and lack of counseling, the number of cirrhotic 
patients is increasing and most of them are admitted to medical wards 
with different complications.  
The syndrome of  hepatic encephalopathy(HE)1 describes all 
neuropsychiatric symptoms occurring in patients with acute or chronic 
liver diseases (CLD) in the absence of other neurological disorders. 
About 30% of patients with cirrhosis die in hepatic coma2. 
Appearance of  HE in any patient is indicative of  poor  prognosis4. 
HE can occur either due to acute liver failure or due to one or more 
precipitating factors in a cirrhotic patient, or it could happen as a result 
of prolonged portal systemic shunting resulting in a chronic portal 
systemic encephalopathy5.  
 
Survival of patients having chronic portal systemic encephalopathy is 
better than those who develop HE acutely (100% vs. 70%)6. However 
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prognosis in the later group can be improved if the precipitating 
factors are recognized early and managed accordingly7.  
Common precipitating factors include gastrointestinal bleeding , 
infection, azotemia, constipation, electrolyte imbalance8  and high 
protein diet. Usage of drugs such as sedatives9, tranquilizers, 
analgesics and diuretics, fulminant hepatic injury, large volume 
paracentesis have all been considered to precipitate encephalopathy in 
an otherwise stable cirrhotic patient.  
Exact pathogenic mechanism involved is unknown till date, however 
the basic processes are failure of hepatic clearance of gut derived 
substances such as ammonia, free fatty acids, mercaptans etc., either 
through hepatocellular failure or shunting, and altered amino acid 
metabolism, both of which result in changes in cerebral transmission 
causing depressed cerebral function10. 
 
This study was aimed at ascertaining the common precipitating factors 
and their frequency in patients presenting with HE. Other objectives 
were to analyse the commonly associated biochemical laboratory 
findings in such patients, to stratify these patients according to Child’s 
classification of CLD, the outcome, and the etiological factors 
involved.   
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                                  AIM OF THE STUDY 
 
This study was carried out with the main objective of ascertaining the 
most common precipitating factor and their frequency in a group of 
patients presenting with hepatic encephalopathy in diagnosed cases of 
cirrhosis of liver of any etiology 
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                                  REVIEW OF LITERATURE 
CIRRHOSIS OF LIVER 
GENERAL CONSIDERATION 
Cirrhosis is diffuse septal fibrosis of the liver, associated with 
regenerative parenchymal nodules and a disturbed intrahepatic  
circulation. Fibrous sheets link portal tract, central zones and  portal tracts 
and central zones. Cirrhosis results from prolonged, widespread but 
patchy hepato-cellular necrosis due to various reason. 
The most important classification of cirrhosis is based on etiology. The 
most common and important causes are prolonged Alcoholic liver disease 
and chronic hepatitis infection with Hepatitis B & C viruses. 
The less important causes Hemochromatosis, α 1 anti trypsin deficiency, 
Wilson’s disease, Cystic fibrosis, Glycogen storage disease, 
Galactosemia, Hereditary fructose intolerance. 
The potentially treatable causes for cirrhosis being wilson’s disease, Budd 
Chiari  Syndrome, Veno Occlusive Disease,  Hepatitis C infection. These 
disease should be diagnosed as early as possible 
CAUSES FOR CIRRHOSIS 
Alcohol 
Chronic Viral Infection 
Drugs and Toxins 
5 
 
Autoimmune Chronic Liver Disease 
METABOLIC CAUSES 
Hemochromotosis 
Α 1 Antitrypsin Deficiency 
Wilson’s disease 
Cystic Fibrosis 
Glycogen Storage Disease 
Galactosemia 
Hereditary Fructose Intolerance 
BILIARY TRACT DISEASE 
Extra hepatic biliary obstruction 
Intra hepatic biliary obstruction 
Primary biliary cirrhosis 
VENOUS OBSTUCTION 
Veno occlusive disease 
Budd chiari  syndrome 
Cardiac failure 
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EPIDEMIOLOGY 
Chronic liver disease and cirrhosis results in 26000-35000 deaths each 
year in india. Many patient die from the disease in the fifth or sixth 
decade of the life. Each year 2000 additional deaths are attributed to 
Fulminant Hepatic Failure(FHF). FHF may be caused by viral 
hepatitis(A&B), Drugs(e.g acetaminophen), autoimmune hepatitis, 
Wilson’s disease and a variety of less common etiologies. Cryptogenic 
causes are responsible for one third of fulminant cases. Patient with the 
syndrome of FHF have a 50-80% mortality unless they are salvaged by 
liver transplantation 
Etiology 
Alcoholic liver disease is still the predominant cause of cirrhosis in india, 
with chronic hepatitis B & C close second. 
Most common cause of cirrhosis in india 
¾ Alcoholic Liver Disease (35%) 
¾ Post infectious causes (30%) 
¾ Cryptogenic causes (18%) 
¾ Post Hepatic & Biliary causes (8%) 
¾ Miscellaneous (9%) 
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The term compensated and decompensated cirrhosis is often used. A 
patient with compensated cirrhosis has no problem with regard to 
cirrhosis while a patient with decompensated cirrhosis either have signs 
of liver cell failure or complication of cirrhosis. 
PATHOPHYSIOLOGY OF HEPATIC CIRRHOSIS 
The development of hepatic cirrhosis reflect a alteration in the normally 
balanced processes of extracellular matrix production and degradation. 
Extracellular matrix the normal scaffolding for cells hepatocytes is 
composed of collagens (especially type 1,III,V), glycoproteins, 
proteoglycans. Stellate cells, located in the peri-sinusoidal are essential 
for the production of extracellular matrix. Stellate cells which were once 
known as Ito cells, lipocytes or peri-sinusoidal cells may become 
activated into collagen forming cells by variety of paracrine factors. Such 
factors are released by hepatocytes, kupffers cell and sinusoidal 
endothelium following liver injury. As an example increase levels of 
cytokine transforming growth factor β 1 is observed in patients with 
chronic hepatitis C and  those with cirrhosis. TGF β 1 in turn stimulate 
stellate cells to produce type 1 collagen. Increased collagen deposition in 
the space of  Disse (the space between hepatocytes and sinusoids) and the 
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diminution of the size of endothelial fenestrae lead to the capillarisation 
of sinusoids. Activated stellate cells also have contractile properties. Both 
capillarisation and constriction of the sinusoids by the stellate cells 
contribute to the development of portal hypertension. Future drug 
strategies to prevent fibrosis should focus on reducing hepatic 
inflammation, inhibiting stellate cell activation, inhibiting the fibrogenic 
activities of stellate cell and degradation of matrix. 
HISTOLOGY : 
The main histological feature are diffuse septal fibrosis and regenerative 
nodules. With micro nodular cirrhosis which is usually obvious in needle 
Biopsy Specimen the nodules are uniformly small and similar in size to 
liver lobules. 
In micronodular cirrhosis the nodules are variable in size and may be 
more than 10 mm. It may not be visible on nodule biopsy as complete 
nodule formation may not be evident. Other histological features, such as 
fragmentation and pattern of fibrosis especially on reticular staining may 
suggest the correct diagnosis. Silver staining may be required to bring out 
the early cirrhosis. Cell necrosis, evidence of active regeneration and 
cellular infiltrate indicate that the etiological agent is still alive. The 
nature of that agent may be evident on histological examination. 
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On taking the biopsy from the histological specimen care should be taken 
to take the biopsy from the nodules visible on ultra sound examination. 
Open biopsy by laproscopic examination often yields better results. 
Endoscopic guided biopsy is also under development 
CLINICAL FEATURES 
Cirrhosis can present without symptoms or signs and may be found 
incidentally. Clues to the presence of cirrhosis and its etiology usually 
comes from history. 
Symptoms 
Jaundice is usually absent in cirrhosis. It suggest either the causative 
agent is still active, that there is reason for decompensation, or a drug 
might have caused further impairment. 
Weakness, easy fatigueagability, tiredness are very  common and 
contribute to the general malaise of cirrhosis though objective evidence of 
weakness is unusual. Anorexia is frequently present. When present it is 
an ominous sign. Weight loss is seen in end stage cirrhosis. 
Nausea and Vomiting are common. A remediable cause should be sought 
first. Vomitus should be examined to rule out haematemesis. 
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Abdominal pain or discomfort is common, usually in the right upper 
quadrant or right lower ribs. Generalized discomfort may occur with 
abdominal distention due to ascites and related to the rate of fluid 
accumulation and tension in the abdominal wall. 
Increased stool frequency or constipation, both may occur in cirrhotics. 
Fluid retention leads to ankles and legs. Pruritis is a important presenting 
feature in primary biliary cirrhosis 
Dyspnoea may be associated with gross ascites. In patient with some type 
of cirrhosis it is associated with fibrosing alveolitis, pulmonary shunting, 
pulmonary hypertension 
Patient with cirrhosis develop spontaneous bleeding from the nose or 
gums. Cirrhotic may develop hepatic encephalopathy. Fever is common 
may have no obvious cause. Depression is common. 
PHYSICAL SIGNS 
Most patients with cirrhosis look well until the late stage of their disease, 
when muscle wasting and loss of adipose tissue may become prominent. 
An acute worsening of appearance should suggest infection or bleeding, 
while more prolonged deterioration results from decompensation. 
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Pallor may be due to recent UGI bleed or iron deficiency anemia due to 
chronic blood loss. Overt jaundice suggest hepatic decompensation and 
usually a ominous sign. 
Cyanosis is uncommon except there is marked pulmonary shunting. Mild 
shunting is common in cirrhotics. Hypertrophic ostoearthropathy may 
also be present. Spider naevi, Palmar erythema, Paper money skin etc are 
found in cirrhosis especially alcoholic cirrhosis. Excessive bruising and 
petechiae are noted when liver function deteriorates. 
Many cirrhotics especially those with hemochromatosis show widespread 
melanin pigmentation with local area of hyperpigmentation. Vitiligo 
appear in autoimmune liver disease. Lichen planus is associated with 
primary biliary cirrhosis 
Gynaecomastia and testicular atrophy are common in cirrhosis especially 
alcoholic cirrhosis or hemochromatosis and is usually associated with 
thinning of hairs and signs of feminization 
Dupuytren’s contracture and Parotid enlargement are seen more common 
in alcoholic cirrhosis. They are more related to alcoholism than to 
cirrhosis 
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Flapping tremors or asterixis may be observed in patient with hepatic 
encephalopathy. Kayser- Fleischer ring is a particular valuable sign to 
look for in the case of Wilson’s disease as it is a potentially treatable 
condition. 
ABDOMINAL SIGN 
Abdomen may distended due to accumulation of fluid or enlargement of 
abdominal organs. Skin over the abdomen may appear dry with 
prominent dilated veins. Multiple dilated veins may be seen. 
Ascites is commonly seen in decompensated cirrhosis. The abdomen 
appears distended and the umbilicus is everted. Shifting dullness is 
present. 
Dilated veins may be seen over the abdominal wall peri-umbilically 
(caput medusa) or over the flanks(Budd Chiari) 
Enlarged liver or spleen can give rise to local bulging of the abdomen. 
The firm cirrhotic liver may be normal, palpable in the early stages 
shrunken in late stages with nodularity. 
Measurement of the liver span is helpful in diagnosis of shrunken liver. 
The normal range is 12-16 cm by western statistics. According to Indian 
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statistics it ranges from 9-14 cm. A shrunken liver is better appreciated by 
ultrasound. Percussion of the abdomen is helpful in diagnosis of ascites 
Auscultation may reveal a bruit of the liver (Hepatoma) or a venous hum 
in the epigastrium (portal Hypertension), a friction rub over the liver 
(tumour) or over the spleen (infarction). A continuous venous hum may 
be auscultable over the epigastrium (Bomgarten Phenomenon). 
In the case of presence of enlarged veins the direction of flow should be 
determined. The presence of the veins and their exact location should be 
plotted. The presence or absence of pedal edema is also significant 
importance in distinguishing between veno-occlusive disease and Budd 
Chiari syndrome 
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INVESTIGATION: 
HAEMATOLOGY 
Routine haematological values may be normal in all cirrhotics. Mild 
anaemia is common. On blood films target cells may be seen and in rare 
cases acanthocytes and other features of haemolysis may be seen. 
The White Cell count tends to fall in patient with cirrhosis, due to 
hypersplenism. If the white cell count is  raised an infection should be 
sought for carefully. The platelet count is usually low in the cirrhotics due 
to  hypersplenism. Coagulation factor are diminished due to 
hepatocellular damage. Factors 2, 7, 9,10 are affected more out of which 
factor 7 is the most affected. And earliest changes occur in factor 7 
concentration. Prothrombin time is prolonged in decompensated 
cirrhotics. 
 
BIOCHEMICAL 
LIVER FUNCTION TEST 
They are of limited value in cirrhosis, as they may be normal. AST and 
ALT 
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are normal in cirrhosis if causative agent is no longer active or with 
effective therapy,(ex Interferon, Ribavarine). In alcoholic cirrhosis the 
AST/ALT ratio is usually greater than 2. In most patients serum alkaline 
phosphatate is normal except in biliary cirrhosis 
The gamma glutamyl transferase level may be increased in alcoholic 
cirrhosis. The serum total bilirubin level is usually normal. But bilirubin 
may be increased in states of increased bilirubin load like haemolysis, 
UGI bleed, certain drugs like steroids. An increased in bilirubin without 
any obvious cause suggest hepatic decompensation. 
Low albumin levels are usually due to reduce hepatic synthesis. However 
it is also due to extracellular volume expansion or due to GI or renal 
causes. 
OTHER BIOCHEMICAL TESTS 
Plasma electrolytes are usually abnormally in cirrhosis and requires close 
monitoring. 
Hyponatremia is common usually due to excess water intake or due to 
preferential salt loss due to diuretic therapy. Hypernatremia is less 
common and may occur with GI bleed, use of lactulose, and with severe 
fluid restriction. 
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Serum potassium is usually normal in cirrhotics. But both hyper and hypo 
kalemia is observed depending upon he type of diuretic instituted. Ex 
spironolactone produces hyperkalemia, While furesemide produces 
hypokalemia. Urine sodium and potassium measurement are useful to 
guide diuretic therapy. The dose of spironolactone should be increased till 
the urine sodium/potassium ratio is grater than 1. 
Hypomagnesemia and Hypophosphatemia is also common in alcoholic 
patient with cirrhosis. The electrolyte abnormality should be diagnosed 
and treated as early as possible. 
In well compensated cirrhosis, the urea level is normal but it falls short 
once decompensation occur due to inadequate hepatic production. So 
renal failure in cirrhosis should be monitored by serum creatinine. Renal 
failure is common in cirrhosis is common due to hypotension, diuretics, 
hepatorenal syndrome etc 
Fasting blood glucose is usually normal, but most of the cirrhosis are 
insulin resistant and have post prandial hyperglycemia. 
The serum cholesterol is normal in cirrhotics. In end stage cirrhosis the 
levels of lecithin cholesterol Acyl transferase falls and cholesterol ester 
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levels falls, while free cholesterol level increase. Cholesterol levels are 
raised in cases of biliary cirrhosis often to very high levels. 
Anti mitochondrial antibody are raised in primary biliary cirrhosis. The 
test is relatively significant for diagnosing primary biliary cirrhosis. 
Anti-smooth muscle antibody and anti LKM antibody are found elevated 
in auto immune hepatitis. Cryoglobulins and gamma globulin levels are 
also found elevated in many cases of cirrhosis due to the more frequent 
incidence of subclinical septecemia 
ANATOMICAL AND PATHOLOGICAL DIAGNOSIS 
The diagnosis of cirrhosis depends on demonstrating widespread nodules 
in the liver combined with fibrosis 
THIS MAY BE DONE BY: 
1. Laproscopy: Visualizes the liver and enables direct biopsy. 
2. Ultrasound: is suggested by dense reflective areas of irregular 
distribution and increased echogenicity. However ultrasound is not 
reliable for diagnosis unless ascites is present. 
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3. CT Scan: Liver size can be assessed and the irregular nodular 
surface seen. Portal and hepatic vessels can be imagined with 
contrast. Ascites can be seen and gall stone can be visualized. 
4. Biopsy:  Reticulin and collagen stains are essential to highlight the 
fibrosis. Variability of liver cell size and presence of nodules with 
fibrous septa help in diagnosis. 
5. Radio Isotope Scanning: in experimental stages 
INVESTIGATION FOR ETIOLOGICAL DIAGNOSIS 
It is important to establish the cause of cirrhosis 
The following investigation are useful 
1. Viral Serology: 
¾ HBsAg 
¾ IgM AND IgG anti HBV Antibody 
¾ IgM AND IgG anti HCV antibody 
¾ HCV RNA TITER 
¾ Liver biopsy 
2. Serum Iron and Hepatic Iron content to rule out hemochromatosis 
3. KF ring by slit lamp, serum and urinary copper to rule out Wilson’s 
disease 
4. Anti-mitochondrial Antibody  
5. Anti Smooth Muscle Antibody 
6. Anti LKM Antibody 
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7. α – Fetoprotein to rule out malignancy 
Complication of cirrhosis 
Major complication 
1. Portal hypertension and ascites: 
These are two of the major complication of cirrhosis but these can be 
caused by non cirrhotic portal fibrosis or extra hepatic portal vein 
thrombosis. 
2. Hepatic Encephalopathy: 
Major cause of cerebral disturbance and coma in cirrhotics. 
Encephalopathy can be caused by other process also. 
3 Hepatocellular carcinoma: 
One of the most serious complication of long standing cirrhosis also had a 
poor prognosis 
4.Infection: 
Important cause for sudden deterioration 
MINOR COMPLICATION: 
¾ Fluid  electrolyte disturbance 
¾ Anaemia & Haemolysis 
¾ Hepatorenal Syndrome 
¾ Hepatopulmonary Syndrome 
¾ Gallstones 
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PROGNOSTIC INDICATORS: 
Child-Turcot-Pugh classification: 
Class A         5-6 points 
Class B         7-9 points 
Class C         10-15 points 
The higher the grade, the worse the prognosis 
Clinical Variable 1 point 2 point 3 point 
Encephalopathy None Stage 1-2 Stage 3-4 
Bilirubin(mg/dl) <2 2-3 > 3 
Albumin(G/dl) >3.5 2.8-3.5 > 2.8 
Prothrombin Time 
Seconds prolonged or 
INR 
< 4 seconds  
or INR <1.7 
4 seconds  
or INR 1.7-2.3 
> 6 seconds or 
INR> 2.3 
Ascites none slight moderate to 
severe 
 
2.COX REGRESSION MODEL 
Poor prognosis is associated with: 
¾ Prolonged Prothrombin Time 
¾ Marked Ascites 
¾ Gastrointestinal Bleeding 
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¾ Advanced Age 
¾ Continuing Alcohol Consumption 
¾ High Serum Bilirubin 
¾ Spontaneous Bacterial Peritonitis 
¾ Ascites 
 
TREATMENT: 
The management of well compensated cirrhosis is directed towards early 
detection of hepatocellular failure. An adequate balanced diet and 
abstinence from alcohol are essential. 
A diet of 1 g of protein per kg of body weight is usually adequate. 
Hepato-protectives are useless. Additional branched chain amino acids 
are of no use. Onset of hepatocellular failure with edema warrants sodium 
restriction, diuretics, etc. Specific treatments to prevent complication 
should be instituted. 
ANTIFIBROTIC THERAPY 
1. Colchicine: Microtubule inhibitor, it’s a relative harmless drug, only 
complication being diarrhea, and some efficacy in preventing 
progression of cirrhosis. 
2. Steroids: Useful in autoimmune hepatitis. Otherwise has no role in 
therapeutics of alcohol cirrhosis. 
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3. Gamma interferon: Efficacy in cirrhosis not proven. Useful in 
treatment of acute and chronic hepatitis 
  
HEPATIC ENCEPHALOPATHY 
 
Hepatic encephalopathy is a potentially reversible, or progressive, 
neuropsychiatric syndrome characterized by changes in cognitive 
function, behavior, and personality, as well as by transient neurological 
symptoms and characteristic electroencephalographic patterns associated 
with acute and chronic live failure. Hepatic encephalopathy is a frequent 
complication of cirrhosis that is usually observed in association with 
severe hepatic insufficiency30. The characteristic presentation is the 
development of acute encephalopathy with an abrupt decline in the level 
of consciousness, manifested as confusion or coma. Frequently, a 
precipitating factors is identified. The treatment of the episode is directed 
toward the correction of the precipitating factor. Once the precipitating 
condition is resolved the encephalopathy also typically disappears, with 
the patient recovering to his or her previous state. However, in patients 
with low reserves of hepatic function, the hepatic encephalopathy can be 
a chronic condition. The low reserve predisposes the patient to 
development of spontaneous hepatic encephalopathy. There is usually a 
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precipitating factor, and the diagnosis and treatment should consider such 
aspects. 
Chronic encephalopathy can manifest as frequent episodes of acute 
encephalopathy (chronic-recurrent encephalopathy)or with persistent 
neurological manifestations prominence of neurological manifestations. 
In practice, the distinction can be difficult because acute episodes coexist 
with the(chronic-persistent encephalopathy). The distinction between the 
two forms is subjective and is reflected in the chronic manifestations; if 
the manifestations are mild, the term “recurrent encephalopathy” should 
be used. On the other hand, if the chronic manifestations are severe, the 
term “persistent encephalopathy” is appropriate. In patients with chronic-
recurrent encephalopathy, episodes can be associated with a precipitant 
factor but generally are spontaneous or related to the termination of 
treatment. It is not infrequent that these episodes are attributed to 
constipation, associated with administration of an in appropriate dose of 
non-absorbable disaccharide. An acute episode of spontaneous 
encephalopathy usually has an abrupt onset and termination. Between 
episodes, the patient can be alert and not display signs of cognitive 
dysfunction, unless he or she is examined by neuropsychological 
Testing31. Not infrequently, the patients present with a mild 
Parkinsonism, characterized by bradykinesia without tremor. Since 
hepatic encephalopathy is a viable option, since to a lesser extent patients 
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can also be treated with surgical portal-systemic shunts, chronic-
persistent encephalopathy is less frequent than the recurrent form. The 
characteristic manifestations of recurrent encephalopathy are the 
development of dementia, severe Parkinsonism or myelopathy that can be 
associated with other neurological manifestations (ataxia, dysarthria, and 
tremor)32. In these patients, the cognitive alterations have a sub-cortical 
pattern: attention deficits, alterations in vision and practice, and the 
apraxia predominate. Most of the time these effects are transient, while 
bradykinesia and symmetric 
rigidity predominate. Hepatic myelopathy presents as a spastic 
paraparesis with signs of a pyramidal involvement, but the senses are 
rarely affected33. 
 
 PATHOGENESIS  
 
For many years, controversy has existed about the origin of the toxins 
responsible for the altered mental state. There has been debate about the 
role of ammonium, synergic toxins, GABA or endogenous 
benzodiazepines in the development of hepatic encephalopathy. Today, it 
has been established that there are peripheral multi-organic alterations, as 
well as alterations in the intercellular communication of the brain, 
produced by alterations in astrocytes. 
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Peripheral alterations 
a. Intestinal 
There is controversy about the role of Helicobacter pylori, which 
produces ammonium in the stomach, in the pathogenesis of hepatic 
encephalopathy. Some trial shave demonstrated a high prevalence of the 
infection in individuals with alcoholic hepatitis who develop hepatic 
encephalopathy, as well as individuals with cirrhosis and chronic 
encephalopathy. However, eradication of H. pylori does not interfere with 
the levels of ammonium in this group of patients, and its contribution to 
the development of hepatic encephalopathy may therefore be minimal. 
b. Portal-systemic communication 
It has been demonstrated that some congenital abnormalities that cause 
portal-systemic shunts in children can be manifested by episodic hepatic 
encephalopathy, even without preexisting hepatic disease. Also, the 
cirrhotic patients with portal-systemic shunts develop encephalopathy 
easily compared with patients without portal-systemic shunts. 
c. Hepatic failure 
There have been many trials reporting that hepatic failure is the main 
cause of the development of hepatic encephalopathy, resulting from 
decreased hepatic functional capacity that diminishes the detoxification of 
ammonium, raising the plasma levels of this element, thereby producing 
the clinical manifestations of these patients. 
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d. Muscle 
A reduction in the muscle mass of cirrhotic patients can predispose them 
to the development of hepatic encephalopathy. Muscle waste is explained 
not only by the presence of hepatic disease and the patient’s nutritional 
status, but also by elevation of some cytokines like tumor necrosis factor-
alpha (TNF-α), which in turn activates transcription factors like NK-a, 
resulting in reduced myosin synthesis. Muscle waste is associated with a 
lower metabolic capacity to detoxify ammonium and glutamine, resulting 
in the development of hepatic encephalopathy. 
Brain alterations 
a. Osmotic 
Some studies have demonstrated that there are osmotic changes in 
patients with cerebral edema and hepatic insufficiency. On one hand the 
brain develops edema, raising intra cerebral pressure and producing 
herniation that can result in death. The glutamine produced because of the 
detoxification of ammonium in the astrocytes is considered an organic 
osmol that can cause edema in the astrocytes. It has been observed that 
the water channel aquaphorin-4 drives water into the cell. There is also 
evidence that the brain adapts to changes during chronic hepatic disease. 
Direct and indirect determinations of the organic osmoles using 
spectroscopy by resonance imaging in humans have demonstrated a loss 
of myo-inositol, taurine and glyceryl-phosphocholine, which are the 
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osmoles used by the astrocytes for the regulation the intracellular 
osmolality. These changes make the brain more vulnerable to a second 
osmotic change. 
b. Axonal communications 
There is also evidence of the important role of astrocytes in maintaining 
normal neuronal function. In hepatic encephalopathy there are no 
morphologic alteration in the neurons. The Alzheimer type II cells 
(astrocytes)can show some abnormalities: reduced activity of transporters 
(glutamate), increased expression of benzodiazepine receptors and 
increased monoamine oxidase (MAO) activity. As a result there are 
alterations in the metabolic communication between astrocytes and other 
cells. For example, astrocytes synthesize neurosteroids which activate 
GABA receptors and endogenous benzodiazepines receptors. 
c. Endothelial communication with astrocytes: brain blood flow and 
hepatic encephalopathy.  
Some experimental models have demonstrated an increase in cerebral 
perfusion in the presence of high levels of ammonium. This can be 
activated by intra-cerebral signals generated after the synthesis of 
glutamine in the astrocytes. Hypothermia and brain edema can also have 
an important role in the low cerebral perfusion demonstrated in 
experimental models. Cirrhotic patients have decreased brain blood flow, 
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probably secondary to peripheral vasodilatation. These alterations can 
cause a decrease in metabolic activity. 
d. Other hypotheses 
There are other hypotheses related to the pathogenesis of hepatic 
encephalopathy: 
• Ammonium 
Ammonium is fundamental to the pathogenesis of hepatic 
encephalopathy. After detoxification of ammonium by the astrocytes 
some neuro-chemical alterations occur. There are many factors that 
interact with ammonium, causing alterations in the astrocytes 
(hyponatremia, cytokine elevations, alterations in the ligands of 
astrocytes), thereby producing an anatomic substrate and neuro-chemical 
synergism that can increase the development of hepatic encephalopathy. 
However, ammonium levels do not correlate with the severity of 
encephalopathy. 
•Endogenous benzodiazepines                                                                     
The role of these substances in the alteration of GABA-ergic 
neurotransmission is not well understood. Some studies with flumazenil 
have not shown significant results; also, ammonium can activate GABA-
ergic pathways by the synthesis of neurosteroids in astrocytes, as stated 
before. 
• False neurotransmitters 
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A decrease in branched-chain amino acids can favor the entrance into the 
brain of aromatic aminoacids, which are precursors of false 
neurotransmitters that alter glutamine synthesis. The clinical experience 
with ramified amino acids is of great interest because it is possible that 
the amino acids have a direct effect in muscle, increasing ammonium 
detoxification. Other neurotransmission pathways involved in the 
development of hepatic encephalopathy are serotonin (5-HT), opiates and 
catecholamines. Other additional factors that can favor the development 
of recurrent hepatic encephalopathy episodes are nutritional status, 
especially in alcoholic patients who can have deficiencies in vitamins and 
micronutrients. One such example is a deficit in zinc, which is a cofactor 
in the urea cycle. Zinc supplementation, using a dose of 600 mg/day, has 
been studied in encephalopathy but has not demonstrated additional 
benefits44. However, it seems reasonable to measure the plasma zinc 
levels and add zinc supplementation when these are low. Another issue 
that has recently been studied is gastric colonization by H. pylori, a 
microorganism that produces urease. Eradication of  H. pylori can be 
beneficial in other diseases, but it is not associated with a lower 
ammonium level or an improvement in hepatic encephalopathy. 
 
To conclude, hepatic encephalopathy is the result of a combination of  
hepato-cellular insufficiency (live failure), toxin accumulation and the 
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establishment of  a portal-systemic shunt. The main precipitating factor 
(without being an specific cause) is an altered level of plasma 
ammonium. The pathogenic mechanism includes the production of false 
neurotransmitters, facilitated sensibility of neurons by γ-aminobutyric 
acid (GABA),increases in the plasma endogenous benzodiazepines, 
diminished activity of urea cycle enzymes secondary to zinc deficiency 
and finally, manganese deposits on the basal ganglia. 
Clinical stage 
Generally, the diagnosis of hepatic encephalopathy is not difficult; the 
neurological exam is the main element to establish the diagnosis. As 
shown below although stage 2 shows symptoms such as lethargy, 
significant confusion and behavioral changes, in stage 1 the behavioral 
changes can be minimal, such as euphoria, confusion or some degree of 
depression. The more advanced stages can be manifested as confusion, 
somnolence and coma. Also, some electroencephalographic changes can 
be found that vary between the presence of triphasic waves and delta 
activity. Recently, an expert group on hepatic encephalopathy described a 
new classification for patients according to the type of hepatic alteration 
that causes the condition35,36 with three different types of encephalopathy 
being considered: 
Type A: Acute liver failure 
Type B: Portal-systemic bypass without intrinsic 
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hepato-cellular disease (the more frequent) 
Type C: cirrhosis and portal hypertension with porto-systemic shunts 
Classification and grades of hepatic encephalopathy. 
Grade I. Euphoria or depression, mild confusion, monotonous voice 
and/or sleep cycle disorders. Asterixis + 
Grade II. Lethargy and/or confusion. Asterixis, triphasic waves on EEG 
Grade III. Severe confusion, incoherent language, semi-stupor but                               
awakes with language. Asterixis, triphasic waves on EEG 
Grade IV. Coma, initially can respond to painful stimuli.Asterixis.Delta 
wave in EEG 
Predisposing factors for development of hepatic encephalopathy. 
Nitrogen products        Metabolic              Drugs                     Other              
GI   bleeding             Hypokalemia       Opiates                    Infections      
Hiperazoemia           Alkalosis              Diazepam              Surgery 
Constipation             Hypoxia               Diuretics             Hepatopathies 
High protein diet     Hyponatremia      Sedatives             Renal failure 
H. pylori                  Hyperkalemia        Phenol             Short-fatty acids 
Uremia                    Dehydration  
 
In a patient with previously stable cirrhosis, hepatic encephalopathy is 
usually a consequence of an easily identified precipitating factor, as 
shown above, with gastrointestinal bleeding the more common etiologic 
factor. The frequency and form of presentation of encephalopathy in the 
same patient allows establishment of a predominant clinical course, 
within three possibilities: 
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1. Episodic: considered a “recurrent encephalopathy” 
with precipitating factors or spontaneous delirium. 
2. Persistent: cognitive deficits, extra-pyramidal manifestations, 
sleep-pattern changes that cab be either mild 
or severe, but always continuous. 
3. Minimal: sub-clinical cases. 
Hepatic encephalopathy is manifested in variable forms and can be 
associated with any neurological alteration, even with focal deficits. 
Frequently, there is cerebral edema that contributes to the clinical picture 
and increases the mortality in the patients with acute or chronic 
encephalopathy. The decrease in attention and changes of mental state 
can evolve to memory disorders, confusion, stupor and to coma; also, the 
varied combination of neurological signs include asterixis, rigidity, 
abnormal reflexes, Babinsky, and rarely, convulsions. One of the earliest 
signs of encephalopathy`is an inversion in the sleep cycle. Ammonium 
level is a key element in the diagnosis of hepatic encephalopathy, 
however its predictive value in cirrhotic patients is limited. Measuring the 
arterial levels and adjustment of the values according to the pH improve 
the predictive value, but these tests cannot be done in all hospitals. 
Recently, a relation between the levels of arterial ammonium and the 
development of brain herniation in acute hepatic failure has been 
demonstrated. Some other studies have shown that levels of more than 
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200 mg/dL of ammonium in hepatic encephalopathy stages III and IV are 
associated with cerebral herniation. However, other studies have shown 
no correlation between ammonium levels and the stage of hepatic 
encephalopathy. Generally, the diagnosis can be done by exclusion. There 
is no specific alteration in the hepatic function tests; the presence of high 
levels of ammonium in an adequate clinical context suggests the 
diagnosis. However, this is only true for hepatic encephalopathy stages III 
and IV (possibly II), in which the values are presented with the objective 
signs described before. This is not true for stages I or II, where objective 
signs cannot be perceived, allowing progression of the underlying 
condition. Also, it has been demonstrated that ammonium levels do not 
correlate with the severity of encephalopathy or with the response to 
treatment. For these reasons, imaging studies are suggested to diagnose 
encephalopathy stage I and stage II (or mild and minimal-persistent). 
Brain resonance imaging can demonstrate manganese deposits at the 
basal ganglia, showing a high resonant globus pallidus. Computed 
tomography is used to examine the presence of atrophy or cerebral 
edema. Positron emission tomography can produce images reflecting 
biochemical or physiological processes. Finally, spectroscopy by 
resonance imaging makes evident the elevations in the spike of 
glutamine/glutamate and diminished myo-inositol and choline. This data 
can help treatment halt the progression of encephalopathy. Certain 
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neuropsychological tests have been approved by the majority of 
investigators but still require formal validation: 
1. Numeric connection A and B 
2. Line drawing 
3. Digital symbols and points following. 
These types of tests have been named the PHES (Psychometric hepatic 
encephalopathy score) and can be done in ten minutes. The main 
objective is to evaluate the reaction time and the accusiocity, visual 
construction, concentration, attention and memory. 
Treatment 
The treatment of patients with chronic hepatic encephalopathy includes 
establishing the therapeutic objectives. In recurrent encephalopathy the 
main objective is to avoid the acute episodes, while in the persistent form 
the objectives are toward improvement of chronic symptoms and quality 
of life. There are objective parameters that allow good characterization of 
the effects of treatment. One such parameter is the number of days that 
the patient’s autonomy is limited compared to his or her basal state (for 
example, whether he or she is able to work, walk, eat or clean him or 
herself without help). According to the optimal level for an individual 
patient, the degree of autonomy loss can be estimated (as an example: 
25% not able to work, 50% not able to walk, 75% needs help to eat). 
There are tables developed to evaluate patients with dementia that can be 
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useful in these circumstances (Barthel scale). In the best case, some 
psychometric tests and neuropsychological testing should also be  done, 
so as to evaluate the effects of the chronic manifestations. The treatment 
of hepatic encephalopathy should be accompanied by the treatment of the 
other complications of cirrhosis. The potential effects of the treatment 
should be considered against the risk of developing hepatic 
encephalopathy. In patients with ascites, it is better to perform 
paracentesis or to use diuretics. When prescribing diuretics, they should 
be used in low doses that can be modified according to the response. It is 
useful to keep a record of the weight of the patient, the diuretic dose and 
the neurological manifestations. The patient and his or her family should 
understand that it is better to have mild edema than frequent development 
of encephalopathy. Between the different choices in the treatment of 
patients with gastrointestinal hemorrhage, endoscopic or pharmacological 
treatments are better options than the ones that increases the portal-
systemic shunts (surgery or TIPS), because between 30 and 40% of the 
patients with TIPS can develop hepatic encephalopathy. The development 
of hepatic encephalopathy is considered a sign of a bad prognosis. For 
this reason, patients who have presented with an episode of hepatic 
encephalopathy should be evaluated as candidates for hepatic 
transplantation6. However, in cases of chronic persistent encephalopathy, 
the decision can be difficult. Dementia and other severe neurological 
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signs such as paraplegia or psychiatric manifestations are considered 
irreversible. There are descriptions of some cases that show improvement 
of lesions after the transplant. The decision should be individualized for 
each patient. One group of patients with chronic encephalopathy is 
characterized by the development of hepatic encephalopathy after the 
surgery for a portal-systemic shunt. Part of the treatment objectives for 
patients with hepatic encephalopathy is the importance of applying some 
general measures to support the patient. nursing care, in selected cases the 
use of prophylactic endotracheal intubation, and during the period of 
altered mental state, proper nutritional support. Also, it is important to 
identify and treat the potential precipitating factors. In the context of 
gastrointestinal hemorrhage, searching for occult fecal blood or clinical 
evidence of hemorrhage, the detection of infections specifically of 
ascites; additionally, correction of renal and electrolytes disturbances, 
avoiding the use of psychoactive medications such as benzodiazepines, 
narcotics and sedatives and preventing constipation with the use of 
laxatives. Besides these measures, the patient should follow some dietary 
recommendations and receive non-absorbable disaccharide. In some 
cases, the use of neomycin, other antibiotics or dopaminergic drugs can 
be useful. However, none of these therapeutic measures has been 
evaluated with clinical trials of appropriate design and a significant 
number of patients. Accordingly, all of these measures have been 
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criticized. However, clinical experience, together with the data presented 
in the scientific literature allows some recommendations about their use. 
Treatment options 
• Diet 1.2 grams of protein/kg/day (1-1.5 grams) 
Non-absorbable disaccharide 
• Lactulose 
• Acute Oral: 45 mL each hour until bowel movement and clinical 
improvement 
• Chronic Oral: 15-45 mL tid or bid continuous until 2 to 3 bowel 
movements per day 
• Lactose 
• Acute 20% enemas 200 g/L liter of isotonic solution until clinical 
improvement 
• Chronic Oral: 30 g tid or bid continuous until 2 to 3 bowel movements 
per day 
• Sodium benzoate Oral: 5 g bid until clinical improvement 
• orinithine-aspartate Oral or IV 9 gr/d until clinical improvement 
Antibiotics 
• Neomycin 
• Acute Oral: 3.6 g/day 1-2 weeks 
• Chronic * Oral: 1-2 g/day 
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• Metronidazole ** Oral: 250 mg/day 
• Flumazenil I.V.: 1 mg 
• Bromocriptine Oral: 30 mg bid Continuous in case of no response 
with other treatments 
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MATERIALS AND METHODS: 
STUDY  DESIGN: 
Prospective, descriptive study 
PLACE & DURATION: 
Department of  Medicine and Gastroenterology, Government Stanley 
Hospital Chennai 
STUDY PERIOD: 
Study was done over a period of one year from june 2007 to june 2008 
PATIENT & PROCEDURE: 
INCLUSION CRITERIA: 
1.Patients with cirrhosis of liver, belonging to either sex 
2.age above 12 years 
3.hepatic encephalopathy including minimal hepatic encephalopathy 
EXCLUSION  CRITERIA: 
1. Patients with psychiatric disorders or on treatment for psychiatric 
disorders 
2.Those with altered sensorium due  to metabolic disease or head injury 
3.Acute alcoholic intoxication and  alcoholic withdrawal  states 
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                                      PROCEDURE 
 
For data collection, a questionnaire was developed. A detailed clinical 
history of the patient was taken regarding the present and past illnesses . 
Questions were asked about gastrointestinal bleeding, including 
haemetemesis and melaena, constipation, vomiting, dirrhoea, oliguria, 
fever, bleeding manifestation, high protein diet, paracentesis and any 
trauma or surgery. Personal history about alcohol consumption was noted 
in along with smoking and i.v drug abuse Use of any sedatives, diuretics, 
tranquilizers, analgesics and cough syrups was also inquired in detail. All 
patients were carefully examined with special attention to jaundice, 
anaemia, fever, asterixes, hydration, pedal odema, and ascites. Detailed 
abdomen system and neurological examination was done on all patients. 
Encephalopathy was graded according to the clinical criteria as given in 
Table A. 
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Table A: Clinical Grades of hepatic encephalopathy 
Grades Description 
 
I Mild confusion, euphoria, anxiety 
or 
depression, reversed sleep rhythm, 
slurred speech 
 
II Drowsiness, lethargy, gross deficits 
in ability to perform mental tasks, 
relatively moderate confusion 
 
III Somnolent but rousable, severe 
confusion, inability to perform 
mental 
tasks. 
 
IV Coma with (IVa) or without (IVb) 
response to painful stimuli 
 
 
For each patient full blood count, liver function tests, renal function tests, 
random blood sugar, serum electrolytes, serum albumin and coagulation 
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profile were carried out. An abdominal ultrasound was done to look for 
liver and splenic size, parenchymal echogenicity, portal vein diameter, 
and ascites. In case of ascites, an ascites tap was also done to look for 
spontaneous bacterial peritonitis. Any evidence of the presence of other 
co-existent complications of cirrhosis liver was also recorded and Child’s 
score was assessed for each patient based on parameters in table B 
Table B: Child Pugh scoring criteria 
Parameters Numerical Score 
 1 2 3 
Ascites none slight moderate to 
severe 
Encephalopathy none slight to 
moderate 
Moderate to 
severe 
Serum 
bilirubin(mg/dl 
<2 2-3 >3 
Albumin (gm/dl) >3.5 2.8-3.5 <2.8 
Prothrombin time 1-3 4-6 >6 
 
 
 
Total numerical score Child Pugh Class 
5-6 -- A 
7-9 -- B 
10-15 -- C 
All patients were followed for the duration of their stay in hospital and 
whether they survived or died at the end of the stay was also recorded. 
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                    OBSERVATION & DATA ANALYSIS 
                    A total of 50 admitted patients, including 48(96%), male and 
02(4%) females, presenting or complicating into hepatic encephalopathy 
were studied. Majority i.e. 43(86%) patients were older than 40 years 
including 41 (82%) males and 02(04%) females in this group. Seven 
(14%) patients were between 20 and 40 years old, all of them were males. 
The age and gender distribution in different clinical presentation grades 
of patients with HE is given in Table 1. 
 
                                      Table – 1 
 
 
                          Table 1: Age and Gender distribution 
 
 
 
Age Male Female 
< 40 years 07 0 
> 40 years 41 02 
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                                  Age and Gender distribution
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Most common presenting clinical features in the patients were ascites. 
Other common presentation is given in table 2  
 
 
                                             Table 2 
 
Clinical features Frequency  
Ascites  46 (92%) 
Anemia  44 (88%) 
Pedal odema 40 (80%) 
Jaundice 34 (68%) 
Spleenomegaly 24 (48%) 
Oliguria 20 (40%) 
Bleeding tendency  14 (28%) 
  
               Table 2: common presenting features in patients  
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When cirrhotic patients were grouped into Child Pugh classification6,64% 
of the patients were found to be in Class C, 28% of patients in Class B, 
8% of patient in class A,as shown in Table 3     
                                  
                                      Table – 3 
 
 
No of patients acc to age 
group 
< 40 years      < 40 years      
Child pugh 
class 
 
No of 
patients 
Percentage(%)
M F M F 
Class A    04      08% 0 0 2 2 
Class B    14      28% 4 0 10 0 
Class C    32      64% 3 0 29 0 
  
            Table 3: Frequency according to child’s classification and 
associated age and gender distribution 
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                                        Table - 4 
 
No of patients acc to age 
group 
< 40 years      < 40 years      
Child pugh 
class 
No of 
patients 
Percentage(%)
M F M F 
Grade 1    04      08% 0 0 2 2 
Grade 2    18      36% 2 0 16 0 
Grade  3    16      32% 1 0 15 0 
      24% 4 0 08 0 Grade 4    12 
     
 
 
 Table 4: Age and gender distribution in different clinical presentation 
grades of patient with hepatic encephalopathy 
 
The precipitating factors of hepatic encephalopathy most commonly 
found in this patients were GI bleeding 30 (60%), electrolyte disturbance 
20 (40%), infection 10 (20%) and constipation 8 (16%).Out of a total of 
fifty patients of HE, no factors could be found in 2 (4%) patients, 18 
(36%) patients had one factor; 16 (30%)  had two factors, while 12 
(24%)patients had more than two precipitating factors. 46 (92%) patients 
have associated ascites, 4(8%) had spontaneous bacterial peritonitis, 6 
(12%)patients had hepatorenal syndrome, while in 1 (2%) patient 
hepatopulmonary syndrome was diagnosed. In the analysis of the 
laboratory findings, hyponatremia, hypokalemia, hypoglycaemia and low 
49 
 
haemoglobin were found in 16 (32%), 10 (20%), 4 (8%), and 44 (88%) 
patients respectively. In 35(70%) patients blood urea was found high 
while creatinine was above normal limits in 31 (62%) patients. 
Hypoalbuminemia (serum albumin <3.3 g/dl) was found in 43 (86%) 
patients. Leukocytosis (total leukocyte count >11000/ µL) was a feature 
in the laboratory data of 20 (40%) patients. The rest of the patients had 
either normal or low TLC count. Coagulation profile was abnormal in a 
fraction of patient with 14 (28%) patients having Prothrombin time >5 
seconds. However thrombocytopenia (platelet count <150,000/ µL) was a 
consistent finding in 36 (72%) patients.  
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                                    Table - 5 
 
Precipitating factor No of patients (%) 
Gastrointestinal bleed  30 (60%) 
Hyponatremia  16 (32%) 
Hypovolemia  10 (20%) 
Infection   10 (20%) 
Hypokalemia   10 (20%) 
Constipation  08 (16%) 
Diarrhoea  04 (08%) 
Metabolic acidosis  04 (08%) 
Diuretics  04 (08%) 
Sedatives  02 (04%) 
Hypoglycemia 02 (04%) 
No factors 02 (04%) 
 
 Table 5: precipitating factors for hepatic encephalopathy 
 
 
HBsAg was found solely positive in 4 (8%), HCV antibodies were found 
positive alone in 8 (16%) patients, 2 (4%) patients had both B and C 
positive, while 38 (76%) had neither B nor C. 38 patients were chronic 
alcoholic taking more than 80 mg of alcohol per day for more than twenty 
years. 
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                                    Table – 6 
  
Etiology of cirrhosis No of patient (%) 
Alcohol Intake 38 (76%) 
Hepatitis C 08 (16%) 
Hepatitis B 04 (08%) 
  
                  Table 6: various etiology factor in cirrhosis of liver  
 
Out of all the 50 patients 34 (48%) died, all of them males. 12 patients 
were in HE grade 3 and 10 patients were in grade 4. All cirrhotic patients 
who expired were found to be in Class C of Child’s  
  
                                            Table - 7 
 
Patient prognosis No of patient (%) 
Expired  34 (68%) 
Revived  16 (32%) 
 
 
Table 7: prognosis of patient with hepatic encephalopathy in this study 
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                                             DISCUSSION 
Hepatic Encephalopathy has never been less than an unsolved mystery for 
physicians and researchers around the globe. Since the time of 
Hippocrates it has been difficult to diagnose and manage any patient of 
hepatic encephalopathy. Although the exact pathogenic mechanism is yet 
to be determined, modern research has proved time and again that 
identifying and removing precipitating factors is still the key step in the 
overall management11. 
 
In our study that was conducted on 50 patients, majority (86%) of 
patients were more than forty years old. Durrani12 had a similar finding 
in the province of  Balochistan,pakistan.  
 
 Male dominance in progression to advanced stages of chronic liver 
disease was found in our patients. Al-Gindan13 also reported the same 
pattern in a study in Saudi Arabia.  
 
The most common cause of Cirrhosis liver in this study is Alcohol intake. 
38(76%) person were alcoholic, compared to 12(24%) non alcoholic.This 
is in conjuction with the studies done in industrialized nations of the west, 
conn18 and faloon19 ,which showed alcohol as the main aetiological 
factor15.  
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Hepatitis B was an uncommon cause of cirrhosis in our study but  
Hepatitis C twice more common than Hepatitis B as a cause of cirrhosis 
of liver in this study. A probable explanation could also be that most of 
our patients were at end stage cirrhosis in which hepatitis C is the 
commonest cause, This is especially true for the province of  Punjab 
where Aisha23 and Khurram25 reveal gastrointestinal bleeding, infection 
and constipation as the main factors.  
  
 
Studies done by Shaikh22 and Hameed24 show electrolyte imbalance 
ranked at the top. Infection, gastrointestinal bleeding and have been 
repeatedly demonstrated as important precipitating factors of HE16,17 a 
fact also borne out by our study. The findings of the frequencies of 
different precipitating factors in different national and international 
studies are given in Table 8. 
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                                                 Table 8 
 
Studies GI 
bleed
(%) 
Infecti
on (%)  
Hyponatremia
(%) 
Hypokalemia
(%) 
Constipatio
n(%) 
Diarrhea
(%) 
Fallon19 33 - -  18 6 - 
Conn18 18 04 - 09 3 12 
Shaik22 56 15 20 70 52 22 
Hameed24 56 28 28 68 52 - 
Souheil20 18 03 - 11 03 - 
Aisha23 76 52 - - 36 - 
Alam14 22 24 24 18 32 - 
Khurram9 31 11 33  33 - 
Present 
study 
60 20 32 20 16 08 
 
 
 
It can be assessed from the table that our findings match those studies 
done in this sub-continent, Out of four foreign studies however reveal 
infection as a less common cause abroad, which is understandably due to 
better hygienic conditions of the patients and hospitals in the western 
countries.   
 
In 4 % patients, no precipitating factors could be found. In such patients 
exploration should include Doppler Ultrasonography to search for large 
spontaneous portosystemic shunts which can be confirmed and treated 
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with angiographic techniques26. Occult precipitating factors such as zinc 
deficiency should also be sought.27  
 
32% of our patients had  hyponatremia and  20% were hypokalemic. This 
was due to the fact that most of them were on diuretics and there was 
associated diarrhoea or vomiting contributing to the electrolyte 
disturbances.  
 
Findings of low haemoglobin, thrombocytopenia and hypoalbuminemia 
correspond well with advanced stages of cirrhosis.28 Raised total 
leukocyte count in 40% of patients, supports infection23 as a common 
precipitant in our settings.  
 
Raised urea and creatinine is seen in 28% of  patients, highlight the fact 
that azotemia is an important pathogenic contributor to the onset of HE29. 
 
The mortality rate in our patients was 68%, which is double than what 
repoted by Sheila Sherlock6. who did expire were mostly in Class C of 
Child’s classification and grade 3 or 4 of hepatic coma. 
 
Gastrointestinal bleeding, electrolyte disturbances, infection, constipation 
are the most common factors of  hepatic encephalopathy in this study. 
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Priority should be given to these factors in terms of hospital funds, 
medicines and human efforts.  
 
Caution must be exercised in putting cirrhotic patients on diuretics. 
 
 Early and effective infection control measures and better hygienic 
conditions in government hospitals are needed to be maintained. 
  
Consistent use of lactulose and fibre should be encouraged to prevent 
constipation. 
 
 More and more endoscopic facilities should be made available 
nationwide for prompt control of gastrointestinal bleeding. 
 
 Most importantly, a more committed effort is the need of the hour to 
control increasing incidence of hepatitis C. 
  
Only then we stand any chance of combating cirrhosis and even worse 
hepatic encephalopathy. 
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                                                 CONCLUSION 
 
1. In this study 96% of  patient were males and 4% of patient were 
females. 
2. 86% of the patients were more than 40 years of age. 
3. Most common etiological factor for cirrhosis of liver was alcohol 
intake.(76%) 
4. Most common clinical presentations were ascites(92%) and 
anaemia(88%). 
5. Most common precipitating factor was GI bleed(60%). 
6. Other important precipitating factor hyponatremia(32%), 
infection(20%), hypovolemia(20%), hypokalemia(20%), 
constipation(16%). 
7. Less common precipitating factors were  dirrhoea(8%), 
diuretics(8%),  acidosis(8%), sedatives(4%),  hypoglycemia(4%). 
8. 36% patients had one precipitating factors for hepatic 
encephalography. 
9. 30% patients had two precipitating factors for hepatic 
encephalography. 
10. 18% patients had more than two precipitating factors for hepatic 
encephalography. 
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11. 4% of patient no precipitating factors was found  for hepatic 
encephalopathy. 
12. Azotemia was also a important precipitating factor seen in 28% of 
patient. 
13. 64% of patient were classified in class C of child-pugh 
classification. 
14. 36% of patients were in grade 2 and 32% of patient were in grade 
3 of hepatic encephalopathy grading. 
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                                       PROFORMA 
 
Name: 
Occupation: 
Age: 
Literacy status: 
Sex: 
Per capita income: 
 
DOA: 
DOD: 
 
Outcome:   Recovered/expired/not known 
 
Clinical Diagnosis: 
 
History: 
Fever 
Altered sleep rhythm 
Malaise 
Anorexia 
Nausea 
Vomiting 
Abdominal pain 
Diarrhea 
Skin rashes 
Pale stools 
Distaste for smoking 
Constipation 
Large protein intake 
Itching 
Cough with sputum 
Burning micturition 
 
Precipitating factors of hepatic encephalopathy 
GI bleed: haemetemesis/malena/ 
Constipation: 
Diarrhea: 
Overdiuresis 
Large paracentesis 
High protein diet 
Surgery 
Hypovolemia 
Hypoxia 
Hyponatremia 
Hypokalemia 
Metabolic alkalosis 
Infections:chest/UTI/SBP 
Drugs:sedative/NSAIDS/cough syrup 
Superimposed acute liver disease 
Past History: 
DM/HT/CAD/PT 
Similar illness 
Contact with cases of viral hepatitis 
Recent surgery 
 
Treatment History: 
IV fluids/injections/admission to hospital 
Large paracentesis: 
Diuretics 
Native treatment 
 
Family History: 
Jaundice 
Liver diseases 
Cancers 
Personal History: 
Diet: 
Smoking: 
Ethanol: 
IV  
drug  
abuse 
Drug intake: sedatives 
Examination: 
Consciousness: conscious/semiconscious/unconscious 
Orientation: person/place/time 
Anaemia: 
Hydration: 
Cyanosis: central/peripheral 
Clubbing: 
Lymphadenopathy: 
Tattoo marks 
Signs of liver disease: 
Jaundice 
Coagulopathy 
Edema legs 
Spider angioma 
Fetor hepaticus 
Palmar erythema 
Asterixis: 
Vital signs: 
Temperature: 
Pulse: 
BP: 
RR: 
Abdomen: 
Oral cavity: 
Parotid gland: 
Dilated veins: 
Liver: 
Spleen: 
Ascites: 
Other systems: 
CNS 
Higher function:  Appearance/behaviorur/attention 
Delusion/hallucination 
Euphoria/ depression 
Orientation:person/place/tim 
Memory: 
Intelligen 
Speech: 
Hepatic encephalopathy stage:1/2/3/4/ 
 
Cranial Nerves 
Motor system: 
Nutrition 
Tone 
Power 
Superficial reflex: 
Deep tendon reflex: 
Sensory system: 
Involuntary movement 
Meningeal sign: 
Skull & spine: 
 
CVS:  S1S2, 
 
RS: 
 
 
 
 
 
 
 
 
 
                                   
 INVESTIGATION 
1)Haemogram 
HB:                    TC:                           DC: 
ESR :                  PCV:                             PLATELET: 
2) Urine:     Alb:         Sugar:              Deposits:                     BS:                        
BP: 
3) LFT:     T.Bil:        D.Bil:              SGOT:                          SGPT:                   
ALP:          S.Alb:                    S.Glb:              GGT: 
4) Coagulation profile:    BT:                  CT:                APTT:               
PT: 
5) RFT: B.Sugar:    Urea:    Creat:       Na:      K:     Cl:     HCO3: 
6) Ascitic fluid analysis:     Glucose:              Cell count:               Culture:          
SAAG:                            Stain: 
7) X-ray chest :                                                      ECG: 
8) USG Abdomen: 
9) Urine culture: 
                         
10) Blood culture:  
 
11) Sputum culture: 
 12) EEG: 
 
13) CT Abdomen: 
 
14) MRI: 
 
15) Other investigation: 
 
                       
TREATMENT  GIVEN  : 
 
 
 
 
 
 
 
 
 
  
ABBREVIATIONS  
 
HE – hepatic encephalopathy 
CLD- chronic liver disease 
HbSAg- hepatitis B antibody 
HCV- hepatitis C virus 
FHF- fulminant hepatic failure 
TIPS- trans jugular intrahepatic porto-systemic shunt 
TGF- tumour growth factor 
PBC- primary biliary cirrhosis 
UGI- upper intestinal bleed 
AST- aspartate transaminase 
ALT- alanine transaminase 
PHT- portal hypertension 
TNF- tumour necrosis factor 
NK- natural killer cells 
H.pylori- helicobacter pylori 
HBV- hepatitis B virus 
EEG- electroencephalography 
Master chart- 1- present 
                       2- absent 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
